London, UK, 3 June 2021
IRLAB Therapeutics (IRLABA): Initiation - Focused on novel Parkinson's disease treatments
IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson's disease (PD). PD is a complex and progressive neurodegenerative condition with huge unmet need. IRLAB has two lead assets in Phase II trials: mesdopetam (D3 antagonist) and pirepemat (PFC enhancer). Both assets have a unique MOA and were developed through its proprietary technology ISP platform to address a wide spectrum of symptoms such as levodopa-induced dyskinesias (PD-LIDs), psychosis and PD-Falls. Top-line data from the mesdopetam US/EU Phase IIb/III trial in PD-LIDs, expected in H122, will define the pivotal trials required for approval. We value IRLAB at SEK4.8bn.
Our valuation of SEK4.8bn or SEK93.3/share is based on a risk-adjusted NPV model for mesdopetam in PD-LIDs (SEK45.9/share) and PD-Psychosis (SEK13.2/share), and pirepemat in PD-Falls (SEK29.3/share). We forecast US/EU launches in 2026 and 2027 respectively; China represents an additional opportunity not reflected in our forecasts. Additionally, we do not include the early-stage portfolio (preclinical assets IRL942 and IRL1009), nor the proprietary ISP platform technology in our valuation. We include net cash of SEK253.9m at 31 March 2021.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Dr Susie Jana +44 (0)20 3077 5700 healthcare@edisongroup.com
Dr John Priestner +44 (0)20 3077 5700 healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
